#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Interaction of 1,4-dihydropyridines with ion channels


Authors: L. Veizerová;  J. Světlík;  V. Kettmann
Authors‘ workplace: Univerzita Komenského, Farmaceutická fakulta, Katedra farmaceutickej analýzy a nukleárnej farmácie, Bratislava
Published in: Čes. slov. Farm., 2008; 57, 58-62
Category: Review Articles

Overview

The pharmacology of dihydropyridines in the cardiovascular system is widely known and the effects on L-type channels are well researched. There is far less information about the action of dihydropyridines on other classes of voltage-gated calcium channels. This article aims to bring more information about dihydropyridine derivates action on voltage-gated calcium channels or on Na⁺ a K⁺channels.

Key words:
Ca²⁺ channels – N-channel blockers – T-channel blockers – 1,4-dihydropyridines


Sources

1. Caterrall, W. A.: Pharmacol. Rev., 2005; 57, 411–425.

2. Josephson, I. R. et al.: Biophys. J., 2002; 83, 2575–2586.

3. Triggle, D. J.: Drug. Dev. Res., 2003; 58, 5–17.

4. Ertel, E. A. et al.: Neuron, 2000; 25, 533–535.

5. Hofmann, F. et al.: Rev. Biochem. Physiol., 1999; 139, 33–88.

6. Yu, F. H., Catterall, W. A.: Sci. STKE, 2004; 253, 15.

7. Tanaka, H., Shigenobu, K.: J. Pharmacol. Sci., 2005; 99, 214–220.

8. Hamid, J. et al.: Neuroscience, 2006; 143, 717–728.

9. Ono, K., Iijima, T.: J. Pharmacol. Sci., 2005; 99, 197–204.

10. Vitko, I. et al.: J. Neurosci., 2005; 25, 4844–4855.

11. Splawski, I. et al.: J. Biol. Chem., 2006; 281 (31), 22085–22091.

12. Yunker, A. M. R.: J. Bioenerg. Biomembr., 2003; 35, 6, 577–598.

13. Hagivara, N. et al.: J. Physiol., 1988; 395, 233–253.

14. Heady, T. N. et al.: Jpn. J. Pharmacol., 2001; 85, 339–350.

15. Masuda, Y. et al.: Cardiovasc. Drug Rev., 1994; 12, 123–135.

16. Masumiya, H. et al.: Eur. J. Pharmacol., 1998; 349, 351–357.

17. Furukawa, T. et al.: Br. J. Pharmacol., 2004; 143, 1050–1057.

18. Tanaka, H. et al.: J. Pharmacol. Sci., 2004; 96, 499–501.

19. Kumar, P. H. et al.: Mol. Pharmacol., 2002; 61, 649–658.

20. Triggle, D. J.: Mini Rev. Med. Chem, 2003; 3, 215–223.

21. Yamamoto, T. et al.: Bioorg. Med. Chem. Lett., 2006; 16, 798–802.

22. Mori, Y. et al.: Trends Cardiovasc. Med., 2002; 12, 270–275.

23. Saegusa, H. et al.: T. EMBO J., 2001; 20, 2349–2354.

24. Perez-Pinzon, M. A. et al.: J. Neurol. Sci., 1997; 153, 22–28.

25. Doering, C. J., Zamponi, G. W.: J. Bioenerg. Biomembr., 2003; 35 (6), 491–505.

26. Hu, L. Y. et al.: J. Med. Chem., 1999; 42, 4239–4249.

27. Roullet, J. B. et al.: J. Biol. Chem., 1999; 274, 25439–25446.

28. Murai, Y. et al.: Brain Res., 2000; 854, 6–10.

29. Murakami, M. et al.: Eur. J. Pharmacol., 2000; 419, 175–181.

30. Hu, W. Y. et al.: J. Cardiovas. Pharmacol., 2001; 38, 450–459.

31. Uneyama, H. et al.: Eur. J. Pharmacol., 1999; 373, 93–100.

32. Takahara, A. et al.: Hypertens. Res., 2003; 26, 741–752.

32a. Altier, Ch., Zamponi, G. W.: Trends Pharmacol. Sci., 2004; 29, 465–470.

33. Mintz, I. M. et al.: Nature, 1992; 355, 827–829.

34. Newcomb, N. et al.: Biochemistry, 1998; 37, 15353–15362.

35. Bourinet, E. et al.: Biophys. J., 2001; 81, 79–88.

36. Ellory, J. C. et al.: FEBS Letts., 1992; 296, 219–221.

37. Ellory, J. C. et al.: Brit. J. Pharmacol., 1994; 111, 903–905.

38. Klockner, U. et al.: Brit. J. Pharmacol., 1989; 97, 957–967.

39. Longman, S. D. et al.: Med. Res. Rev., 1992; 35, 2327–2340.

40. Li, J. H.: Cardiovascular Drug Reviews, 1997; 15, 220–231.

41. Yagupolskii, L. M. et al.: J. Med. Chem., 1999; 42, 5266–5271.

42. Kohlhardt, M. et al.: Naunyn–Schmied. Arch. Pharmacol., 1989; 340, 210–218.

43. Yatani, A. et al.: Circ. Res., 1985; 57, 868–875.

44. Haleen, S. J. et al.: J. Pharmacol. Exp. Therap., 1989; 250, 22–30.

Labels
Pharmacy Clinical pharmacology
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#